{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:28:40Z","timestamp":1784662120093,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011541","name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Estimates of contralateral breast cancer (CBC) risk in the modern treatment era by year of diagnosis and characteristics of the first breast cancer are needed to assess the impact of recent advances in breast cancer treatment and inform clinical decision making.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We examined CBC risk among 419,818 women (age 30\u201384\u2009years) who were diagnosed with a first unilateral invasive breast cancer and survived \u2265\u20091\u2009year in the US Surveillance, Epidemiology, and End Results program cancer registries from 1992 to 2015 (follow-up through 2016). CBC was defined as a second invasive breast cancer in the contralateral breast \u2265\u200912\u00a0months after the first breast cancer. We estimated standardized incidence ratios (SIRs) of CBC by year of diagnosis, age at diagnosis, and tumor characteristics for the first breast cancer. Cumulative incidence of CBC was calculated for women diagnosed with a first breast cancer in the recent treatment era (2004\u20132015, follow-up through 2016).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Over a median follow-up of 8\u2009years (range 1\u201325\u2009years), 12,986 breast cancer patients developed CBC. Overall, breast cancer patients had approximately twice the risk of developing cancer in the contralateral breast when compared to that expected in the general population (SIR\u2009=\u20092.21, 95% CI\u2009=\u20092.17\u20132.25). SIRs for CBC declined by year of first diagnosis, irrespective of age at diagnosis and estrogen receptor (ER) status (<jats:italic>p<\/jats:italic>-trends &lt;\u20090.001), but the strongest decline was after an ER-positive tumor. The 5-year cumulative incidence of CBC ranged from 1.01% (95% CI\u2009=\u20090.90\u20131.14%) in younger women (age\u2009&lt;\u200950\u2009years) with a first ER-positive tumor to 1.89% (95% CI\u2009=\u20091.61\u20132.21%) in younger women with a first ER-negative tumor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Declines in CBC risk are consistent with continued advances in breast cancer treatment. The updated estimates of cumulative incidence inform breast cancer patients and clinicians on the risk of CBC and may help guide treatment decisions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-021-01400-3","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T08:00:13Z","timestamp":1613635213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992\u20132016"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2007-2840","authenticated-orcid":false,"given":"Cody","family":"Ramin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana R.","family":"Withrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittny C.","family":"Davis Lynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen L.","family":"Gierach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Berrington de Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"1400_CR1","volume-title":"Breast cancer facts & figures, 2019\u20132020","author":"American Cancer Society","year":"2019","unstructured":"American Cancer Society. Breast cancer facts & figures, 2019\u20132020. Atlanta: American Cancer Society, Inc.; 2019."},{"key":"1400_CR2","unstructured":"Curtis RE, Hankey BF, Hoover RN. New malignancies following breast cancer. In: Curtis RE, Ron E, LAG R, Hacker DG, Edwards BK, Tucker MA, Fraumeni Jr JF, editors. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. Bethesda: National Cancer Institute; NIH publication 05-5302; 2006:181\u2013205."},{"issue":"5","key":"1400_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/01.ede.0000072105.39021.6d","volume":"14","author":"JL Bernstein","year":"2003","unstructured":"Bernstein JL, Lapinski RH, Thakore SS, Doucette JT, Thompson WD. The descriptive epidemiology of second primary breast cancer. Epidemiology. 2003;14(5):552\u20138.","journal-title":"Epidemiology."},{"issue":"12","key":"1400_CR4","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2010.32.7395","volume":"29","author":"HB Nichols","year":"2011","unstructured":"Nichols HB, Gonz\u00e1lez ABd, Rosenberg PS, Anderson WF. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29(12):1564\u20139.","journal-title":"J Clin Oncol"},{"issue":"9132","key":"1400_CR5","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","volume":"352","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352(9132):930\u201342.","journal-title":"Lancet"},{"key":"1400_CR6","doi-asserted-by":"crossref","unstructured":"Kramer I, Schaapveld M, Oldenburg HSA, Sonke GS, McCool D, van Leeuwen FE, Van de Vijver KK, Russell NS, Linn SC, Siesling S et al. The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype. J Natl Cancer Inst. 2019;111(7):709\u201318.","DOI":"10.1093\/jnci\/djz010"},{"issue":"18","key":"1400_CR7","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/JCO.2011.40.1273","volume":"30","author":"SH Giordano","year":"2012","unstructured":"Giordano SH, Lin Y-L, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. J Clin Oncol. 2012;30(18):2232\u20139.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1400_CR8","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673\u201384.","journal-title":"N Engl J Med"},{"issue":"16","key":"1400_CR9","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659\u201372.","journal-title":"N Engl J Med"},{"key":"1400_CR10","doi-asserted-by":"crossref","unstructured":"Murphy JA, Milner TD, O'Donoghue JM. Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol. 2013;14(7):e262\u20139.","DOI":"10.1016\/S1470-2045(13)70047-0"},{"issue":"3","key":"1400_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/SLA.0000000000001698","volume":"265","author":"SM Wong","year":"2017","unstructured":"Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg. 2017;265(3):581\u20139.","journal-title":"Ann Surg"},{"issue":"1","key":"1400_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamasurg.2014.2895","volume":"150","author":"KL Kummerow","year":"2015","unstructured":"Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surgery. 2015;150(1):9\u201316.","journal-title":"JAMA Surgery"},{"key":"1400_CR13","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 13 Regs excluding AK Research Data, Nov 2018 Sub (1992\u20132016) <Katrina\/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969\u20132017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission."},{"key":"1400_CR14","unstructured":"Fraumeni JF, Curtis RE, Edwards BK, Tucker MA: Introduction. In: Curtis RE, Freedman MD, Ron E, Ries LA, Hacker D, Edwards BK, Tucker MA, Fraumeni JF, editors. New malignancies among cancer survivors: SEER cancer registries, 1973\u20132000. Bethesda, MD: National Cancer Institute, NIH publication 05\u20135302; 2006: 1\u20137."},{"issue":"9","key":"1400_CR15","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1097\/MLR.0000000000000073","volume":"54","author":"A-M Noone","year":"2016","unstructured":"Noone A-M, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, Warren JL. Comparison of SEER treatment data with medicare claims. Med Care. 2016;54(9):e55\u201364.","journal-title":"Med Care"},{"key":"1400_CR16","unstructured":"Curtis RE, Ries LA: Methods. In: Curtis RE, Freedman MD, Ron E, Ries LA, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF, editors. New malignancies among cancer survivors: SEER cancer registries, 1973\u20132000. Bethesda: National Cancer Institute, NIH publication 05\u20135302; 2006: 9\u201313."},{"key":"1400_CR17","unstructured":"Breslow NE, Day NE: Statistical methods in cancer research. Volume II: The design and analysis of cohort studies. IARC Scientific Publication 82; 1987."},{"issue":"2","key":"1400_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0378-5122(95)00968-X","volume":"23","author":"K Hill","year":"1996","unstructured":"Hill K. The demography of menopause. Maturitas. 1996;23(2):113\u201327.","journal-title":"Maturitas."},{"issue":"6","key":"1400_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695\u2013706.","journal-title":"Stat Med"},{"key":"1400_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1536867X0400400201","volume":"4","author":"V Coviello","year":"2004","unstructured":"Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J. 2004;4:103\u201312.","journal-title":"Stata J"},{"issue":"10001","key":"1400_CR21","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2015","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341\u201352.","journal-title":"Lancet"},{"key":"1400_CR22","doi-asserted-by":"crossref","unstructured":"Gierach GL, Curtis RE, Pfieffer RM, Mullooly M, Ntowe EA, Hoover RN, Nyante SJ, Feigelson HS, Glass AG, de Gonzalez AB. Association of adjuvant tamoxifen and aromatase inhibitor therapy with contralateral breast cancer risk among us women with breast cancer in a general community setting. JAMA Oncol. 2017;3(2):186\u201393.","DOI":"10.1001\/jamaoncol.2016.3340"},{"issue":"9793","key":"1400_CR23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2011","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771\u201384.","journal-title":"Lancet"},{"issue":"8","key":"1400_CR24","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1200\/JCO.1993.11.8.1545","volume":"11","author":"EA Healey","year":"1993","unstructured":"Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol. 1993;11(8):1545\u201352.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1400_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/82533","volume":"26","author":"J Peto","year":"2000","unstructured":"Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet. 2000;26(4):411\u20134.","journal-title":"Nat Genet"},{"issue":"4","key":"1400_CR26","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S0360-3016(03)00203-7","volume":"56","author":"X Gao","year":"2003","unstructured":"Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiation Oncol Biol Physics. 2003;56(4):1038\u201345.","journal-title":"Int J Radiation Oncol Biol Physics"},{"issue":"18","key":"1400_CR27","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/jnci\/djr257","volume":"103","author":"WF Anderson","year":"2011","unstructured":"Anderson WF, Katki HA, Rosenberg PS. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst. 2011;103(18):1397\u2013402.","journal-title":"J Natl Cancer Inst"},{"key":"1400_CR28","doi-asserted-by":"crossref","unstructured":"Aalders KC, van Bommel ACM, van Dalen T, Sonke GS, van Diest PJ, Boersma LJ, van der Heiden, van der Loo M. Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. Eur J Cancer. 2016, 63:118\u2013126.","DOI":"10.1016\/j.ejca.2016.05.010"},{"key":"1400_CR29","doi-asserted-by":"crossref","unstructured":"Hooning MJ, Aleman BMP, Hauptmann M, Baaijens MHA, Klijn JGM, Noyon R, Stovall M, van Leeuwen FE. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol. 2008, 26(34):5561\u20135568.","DOI":"10.1200\/JCO.2007.16.0192"},{"issue":"1","key":"1400_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-007-9709-2","volume":"110","author":"M Schaapveld","year":"2008","unstructured":"Schaapveld M, Visser O, Louwman WJ, Willemse PHB, de Vries EGE, van der Graaf WTA, Otter R, Coebergh JWW, van Leeuwen FE. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008;110(1):189\u201397.","journal-title":"Breast Cancer Res Treat"},{"issue":"10075","key":"1400_CR31","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, et al. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195\u2013205.","journal-title":"Lancet"},{"issue":"1","key":"1400_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1010661514306","volume":"67","author":"E Janschek","year":"2001","unstructured":"Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S, Rudas M, Gnant M, Jakesz R. Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat. 2001;67(1):1\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1400_CR33","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ijc.31051","volume":"142","author":"CB Begg","year":"2018","unstructured":"Begg CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, Ng CKY, Sakr RA, Bernstein JL, Burke KA, King TA, Piscuoglio S, et al. Contralateral breast cancers: independent cancers or metastases? Int J Cancer. 2018;142(2):347\u201356.","journal-title":"Int J Cancer"},{"issue":"2","key":"1400_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10549-015-3403-6","volume":"151","author":"D Klevebring","year":"2015","unstructured":"Klevebring D, Lindberg J, Rockberg J, Hilliges C, Hall P, Sandberg M, Czene K. Exome sequencing of contralateral breast cancer identifies metastatic disease. Breast Cancer Res Treat. 2015;151(2):319\u201324.","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-021-01400-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-021-01400-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-021-01400-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T10:19:15Z","timestamp":1619173155000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-021-01400-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1400"],"URL":"https:\/\/doi.org\/10.1186\/s13058-021-01400-3","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"14 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used de-identified data from the National Cancer Institute\u2019s Surveillance, Epidemiology and End Results program and informed consent was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}